A controlled trial of renal denervation for resistant hypertension.

  title={A controlled trial of renal denervation for resistant hypertension.},
  author={Deepak L. Bhatt and David E. Kandzari and William W. O’Neill and Ralph B. D'Agostino and John M. Flack and Barry T. Katzen and Martin B. Leon and Minglei Liu and Laura Mauri and Manuela Negoita and Sidney A. Cohen and Suzanne Oparil and Krishna J. Rocha-Singh and Raymond R. Townsend and George L. Bakris},
  journal={The New England journal of medicine},
  volume={370 15},
BACKGROUND Prior unblinded studies have suggested that catheter-based renal-artery denervation reduces blood pressure in patients with resistant hypertension. METHODS We designed a prospective, single-blind, randomized, sham-controlled trial. Patients with severe resistant hypertension were randomly assigned in a 2:1 ratio to undergo renal denervation or a sham procedure. Before randomization, patients were receiving a stable antihypertensive regimen involving maximally tolerated doses of at… 

Figures and Tables from this paper

Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial

Although blood pressure reduction after renal denervation was similar to other sham-controlled studies, the sham group in this study showed much greater reduction than expected, highlighting study design issues that will be addressed in a new trial.

Randomized Sham-Controlled Trial of Renal Sympathetic Denervation in Mild Resistant Hypertension

In patients with mild resistant hypertension, renal sympathetic denervation failed to show a significant reduction in the primary end point of 24-hour systolic BP at 6 months between groups in the intention to treat analysis.

Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3.

Effects of renal denervation on blood pressures in patients with hypertension: a systematic review and meta-analysis of randomized sham-controlled trials

The data from randomized sham-controlled trials showed that renal denervation significantly reduced all blood pressure metrics in medicated or unmedicated patients with hypertension, including resistant/uncontrolled hypertension.

Renal Denervation for Resistant Hypertension: Blinded or Unblinding Recent Trial?

According with a review and meta-analysis of 12 studies, renal denervation in a total population of 561 patients with resistant hypertension, resulted in a significant reduction in mean blood pressure at 6 months.

The Future of Renal Denervation in Resistant Hypertension

Catheter-based radio-frequency renal denervation is already widely available outside of the USA for commercial use, but its utility in resistant hypertension must be vetted by further rigorous investigation before its use can be routinely recommended.

Renal Denervation for Resistant Hypertension in the contemporary era: A Systematic Review and Meta-analysis

The meta-analysis of 15 RCTs showed no significant benefit of RDN on blood pressure control in patients with resistant hypertension, and subgroup analysis of sham control studies showed a modest benefit in 24 hr. systolic blood pressure at 6 months with RDN.

Renal denervation in the most serious form of resistant arterial hypertension.

In a small group of patients with severe hypertension, it is demonstrated that renal sympathetic denervation is capable of reducing blood pressure even in patients withsevere hypertension.

Renal denervation improves exercise blood pressure: insights from a randomized, sham-controlled trial

Exercise systolic BP values in patients with mild therapy-resistant hypertension are reduced after RSD as compared to a sham-procedure, a known predictor for future cardiovascular events.



Renal Sympathetic Denervation for Treatment of Drug-Resistant Hypertension: One-Year Results From the Symplicity HTN-2 Randomized, Controlled Trial

Control patients who crossed over to renal denervation with the Symplicity system had a significant drop in blood pressure similar to that observed in patients receiving immediate denervation, which provides safe and sustained reduction of blood pressure to 1 year.

Catheter‐Based Renal Denervation for Resistant Hypertension: Rationale and Design of the SYMPLICITY HTN‐3 Trial

The SYMPLICITY HTN‐3 Trial is a pivotal study designed as a prospective, randomized, masked procedure, single‐blind trial evaluating the safety and effectiveness of catheter‐based bilateral renal denervation for the treatment of uncontrolled hypertension despite compliance with at least 3 antihypertensive medications of different classes at maximal tolerable doses.

Addition of Spironolactone in Patients With Resistant Arterial Hypertension (ASPIRANT): A Randomized, Double-Blind, Placebo-Controlled Trial

In conclusion, spironolactone is an effective drug for lowering systolic BP in patients with resistant arterial hypertension.

Renal Denervation Therapy for Hypertension

An overweight 78-year-old man with hypertension treated with spironolactone, amlodipine, lisinopril, and extended-release metoprolol, intolerant of multiple antihypertensives including clonidine, is referred for renal sympathetic denervation (RSDN).

Divergent Results Using Clinic and Ambulatory Blood Pressures: Report of a Darusentan-Resistant Hypertension Trial

It is concluded that darusentan provided greater reduction in systolic BP in resistant hypertension patients as assessed by ambulatory BP monitoring, in spite of not meeting its coprimary end points.

Renal Sympathetic Denervation Therapy for Resistant Hypertension: A Contemporary Synopsis and Future Implications

This review focuses on the evolution of renal sympathetic denervation (RSDN) therapy; its role in the management of RHTN; current trial data; the wider application of renal denervation in the treatment of heart failure, arrhythmia, and the metabolic syndrome; and emerging technologies for this potential device-based standard of care.

Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis.

The presence of resistant hypertension identifies a subgroup of patients with hypertension and atherothrombosis who are at heightened risk for adverse long-term outcomes.